EMR vs HUBB: Which Is the Better Buy in 2026?

Last updated November 2026

Short answer

EMR is the larger of the two ($84.07B market cap): the incumbent the market prices for continued execution (19.05x forward earnings, beta 1.21). HUBB is the smaller challenger ($21.54B), priced similarly on forward earnings (17.68x): more room to run, but more to prove. HUBB is expected to grow revenue faster (11% vs 5% next year) at a similar price (17.68x vs 19.05x forward earnings). The case for EMR rests on its own driver (Automation pure-play transformation): if you believe in that, EMR fits; if you believe in what the numbers show today, HUBB does.

EMR vs HUBB: the tie-breaker metrics

Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

MetricEMRHUBBWhat it tells you
Market cap$84.07B$21.54BSize. The larger name is the incumbent; the smaller has more room to grow and more to prove.
Forward P/E19.0517.68Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up.
Trailing P/E31.9923.92Valuation on the last 12 months. A big drop from trailing to forward means the market expects earnings to jump, so more growth is already in the price.
Beta1.210.84Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through.
Price vs 52-week range62% of range2% of rangeWhere today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why.
Price / book4.125.25How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price.

Before you buy: how EMR and HUBB affect your concentration

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. EMR and HUBB share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined EMR and HUBB exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

What does Emerson Electric (EMR) do?

Emerson Electric is a global industrial-technology company focused on automation, helping manufacturers and process industries run their plants more efficiently, safely, and reliably. Over the past several years Emerson has transformed itself from a diversified industrial conglomerate into a more focused automation pure-play, divesting legacy businesses like its commercial and residential climate-technologies unit and acquiring software and measurement assets. Its core products include process control systems, measurement and analytical instruments, valves and actuators, software for plant operations, and test and measurement equipment, much of it sold under brands like DeltaV, Rosemount, Fisher, AspenTech, and NI (National Instruments). Customers span energy, chemicals, life sciences, power, water, food and beverage, and discrete manufacturing. Emerson makes money by selling this hardware and software plus recurring service, software subscriptions, and aftermarket parts, with a meaningful share of revenue tied to keeping installed systems running. The shift toward higher-margin software and recurring revenue, anchored by AspenTech, is central to its strategy. Emerson is headquartered in St. Louis, Missouri.

Full EMR guide

What does Hubbell Incorporated (HUBB) do?

Hubbell Incorporated makes the physical components that connect, protect, and manage electrical power. It runs two segments: Utility Solutions (roughly $3.7 billion of 2025 sales), which supplies grid infrastructure for transmission and distribution, substations, telecom, and gas, and Electrical Solutions (roughly $2.1 billion), which serves industrial, commercial, and increasingly data center customers with wiring, enclosures, connectors, and controls. Total 2025 revenue was about $5.8 billion, and trailing twelve-month revenue reached about $6.6 billion by September 2026, with the third quarter up about 25% year over year to about $1.87 billion. The company sells largely into utilities and electrical contractors, giving it exposure to long-cycle infrastructure spending rather than fast-moving consumer demand.

Full HUBB guide

EMR vs HUBB: how do they differ?

Both fit overlapping themes, but they are not interchangeable. Here is what each one depends on.

  • EMR drivers: Automation pure-play transformation; Software and recurring revenue.
  • HUBB drivers: Grid modernization and T&D spending; Electrification and data center demand.

Which fits which kind of investor

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: Emerson's end markets are cyclical and tied to industrial capital spending, energy and chemical capex, and the global economy, so downturns can slow orders and revenue. For HUBB, hubbell trades at a premium valuation, so any slowdown in utility capital spending, telecom, or data center demand could compress both earnings and the multiple; the stock's roughly 28% fall from its 52-week high shows the multiple already contracting.

EMR or HUBB: which should you pick?

If the story you believe is EMR's (Automation pure-play transformation), EMR is the more direct way to own it; if it is HUBB's (Grid modernization and T&D spending), HUBB is. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the EMR and HUBB guides.

EMR vs HUBB: the full fundamentals

EMR. Emerson closed near $153 on November 20, 2026, about 11% below its 52-week high of ~$172 after a ~13% YTD gain, and trades at about 21 times fiscal 2027 consensus earnings of ~$7.31 and ~16 times EV/EBITDA, a premium to the average industrial. The market is paying for the software-heavy mix, ~25% operating margins and steady (if narrow) beats. The 28 analysts Yahoo tracks average a buy rating with a target near $183, and consensus for fiscal Q1 2027 is ~$1.62 EPS on ~$4.59 billion of revenue.

HUBB. At about $407, Hubbell trades near 24x trailing and 18x forward earnings, down from about 28x and 20x in October, as the share price fell while estimates held. Q3 2026 adjusted EPS of $5.91 beat the $5.75 estimate, and analysts expect about $5.23 for Q4 and roughly 12% EPS growth in 2027. The roughly 1.5% dividend yield reflects a long history of steady increases more than a high-income profile, and the 13 analysts covering the stock average a target near $538.

Headline figures (approximate, November 2026): EMR shows revenue (fy2026, sept year end) ~$18.98B, up ~5%, revenue growth (sept 2026 qtr, yoy) ~+7%, operating margin ~25%, net income (fy2026) ~$2.69B (~14% margin); HUBB shows revenue (ttm) ~$6.6B, revenue growth (q3 2026, yoy) ~25%, to ~$1.87B, operating / net margin (ttm) ~20% / ~13.8%, eps (trailing / 2026 / 2027 consensus) ~$17.05 / ~$20.59 / ~$23.07.

The bottom line: EMR vs HUBB

EMR and HUBB are related but distinct: same themes, different businesses and risks. Neither wins in the abstract, and whichever you pick is worth sizing so one theme does not take over your portfolio. Walnut can show your combined EMR and HUBB exposure against your real portfolio. It is not an investment adviser.

Wondering how EMR or HUBB fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about Emerson Electric

Ask Walnut's AI anything about EMR and see how it fits what you own.

FAQ

What is the difference between EMR and HUBB?

+

Emerson Electric is a global industrial-technology company focused on automation, helping manufacturers and process industries run their plants more efficiently, safely, and reliably. Hubbell Incorporated makes the physical components that connect, protect, and manage electrical power. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.

Is EMR or HUBB the better stock?

+

Neither is universally better. EMR is the larger incumbent; HUBB is the smaller challenger and looks cheaper on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.

Which is cheaper, EMR or HUBB?

+

On forward P/E (as of November 2026), EMR trades at 19.05x and HUBB at 17.68x, so HUBB is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.

Should you own both EMR and HUBB?

+

Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.

What are the risks of EMR vs HUBB?

+

EMR: Emerson's end markets are cyclical and tied to industrial capital spending, energy and chemical capex, and the global economy, so downturns can slow orders and revenue. The transformation through large acquisitions like AspenTech and NI carries integration, execution, and valuation risk, and the company took on debt and complexity to fund deals (about $12.9 billion of debt against ~$1.8 billion of cash, plus a EUR750 million bond issued in November 2026). Competition in automation and industrial software is intense, including from larger and lower-cost rivals. Foreign-exchange effects, supply-chain disruptions, and project delays can pressure results. The stock trades at about 32 times trailing and 21 times fiscal 2027 consensus earnings, and fiscal Q4 beat estimates by only a cent, so there is limited room for disappointment; the shares fell about 5% over the month to November 20, 2026, and the payoff from the software pivot must still prove out fully. HUBB: Hubbell trades at a premium valuation, so any slowdown in utility capital spending, telecom, or data center demand could compress both earnings and the multiple; the stock's roughly 28% fall from its 52-week high shows the multiple already contracting. Earnings have grown much more slowly than sales: Q3 2026 revenue rose about 25% while trailing earnings growth was only about 4% year over year, so margin conversion on acquired revenue matters, and Electrical Solutions margins have been under pressure. Meters and AMI markets have been weak, and utility ordering patterns can be lumpy and subject to destocking. The large NSI acquisition adds integration and leverage risk, with debt near $5.3 billion and a debt-to-equity ratio near 1.3x. As an industrial manufacturer, Hubbell is exposed to input cost inflation, tariffs, supply chain disruption, and a broader capital spending or macro downturn. Competition from larger and specialized players can pressure share and pricing over time.

Related comparisons

Browse all stock comparisons.

Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell EMR or HUBB; figures are approximate and dated (as of November 2026). Verify current data before investing.